Stockscreener 앱 받기
5.64
2.59%
-0.15
시간 외 거래:
5.70
0.06
+1.06%
전일 마감가:
$5.79
열려 있는:
$5.75
하루 거래량:
839.68K
Relative Volume:
0.63
시가총액:
$642.17M
수익:
-
순이익/손실:
$-242.30M
주가수익비율:
-2.2742
EPS:
-2.48
순현금흐름:
$-192.10M
1주 성능:
+15.57%
1개월 성능:
-3.92%
6개월 성능:
-38.76%
1년 성능:
-35.91%
1일 변동 폭
$5.54
$5.80
1주일 범위
$5.03
$6.10
52주 변동 폭
$3.72
$12.61
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
COGT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
5.64 | 555.62M | 0 | -242.30M | -192.10M | -2.48 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Nuveen Asset Management LLC Has $2.44 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
ProShare Advisors LLC Increases Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.7% – Time to Sell? - Defense World
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $25.00 at JPMorgan Chase & Co. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Shares Up 11.6% Following Analyst Upgrade - Defense World
COGT: JP Morgan Raises Price Target for Cogent Biosciences | COG - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Glob - GuruFocus
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - GlobeNewswire
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference | COGT Stock News - GuruFocus
JPMorgan Ups Price Target for Cogent Biosciences (COGT) to $25 | - GuruFocus
Deutsche Bank AG Reduces Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Jane Street Group LLC Decreases Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year - simplywall.st
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
BNP Paribas Financial Markets Buys Shares of 66,784 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Janus Henderson Group PLC Has $227,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Q2 EPS Estimate for Cogent Biosciences Raised by Analyst - Defense World
Brokerages Set Cogent Biosciences, Inc. (NASDAQ:COGT) PT at $14.29 - Defense World
HC Wainwright Has Lowered Expectations for Cogent Biosciences (NASDAQ:COGT) Stock Price - Defense World
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted P - GuruFocus
Cogent Biosciences (COGT) Maintains 'Buy' Rating with Adjusted Price Target | COGT Stock News - GuruFocus
Cogent Biosciences (COGT) Price Target Reduced by H.C. Wainwrigh - GuruFocus
Northern Trust Corp Grows Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Where are the Opportunities in (COGT) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Has $388,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade - MSN
Voya Investment Management LLC Sells 2,333 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now - MSN
Hsbc Holdings PLC Purchases Shares of 10,674 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Q2 EPS Estimate for Cogent Biosciences Lifted by Analyst - Defense World
Dimensional Fund Advisors LP Lowers Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Research Analysts Offer Predictions for COGT FY2028 Earnings - Defense World
Robert W. Baird Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $7.00 - Defense World
Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Cogent Biosciences (COGT) Maintains Neutral Rating Amid PT Adjus - GuruFocus
Stock Surge: Cogent Biosciences Inc (COGT) Closes at 4.70, Marking a -15.62 Increase/Decrease - DWinneX
Cogent Biosciences (COGT) Maintains Neutral Rating Amid PT Adjustment | COGT Stock News - GuruFocus
Cogent Biosciences (COGT) Price Target Reduced by Baird | COGT Stock News - GuruFocus
Cogent Biosciences Advances with Promising Clinical Trials - TipRanks
MetLife Investment Management LLC Has $443,000 Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Wedbush Trims Price Target on Cogent Biosciences to $10 From $11, Maintains Neutral Rating - marketscreener.com
Cogent Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cogent Biosciences Inc (COGT) Q1 2025 Earnings: EPS Misses at -0 - GuruFocus
Cogent Biosciences (COGT) Plans Strategic Data Announcements in 2025 | COGT Stock News - GuruFocus
Cogent Biosciences Reports First Quarter 2025 Financial Results - GlobeNewswire
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
BRIEF-Cogent Biosciences Q1 Income From Operations USD -74.933 Million - TradingView
Cogent Biosciences Gears Up for 3 Major Clinical Trial Readouts in 2025, Maintains Strong $245M Cash Reserve - Stock Titan
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
0.54%
자본화:
|
볼륨(24시간):